Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Share-based Compensation: 2023-2025

Historic Share-based Compensation for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $15.0 million.

  • NewAmsterdam Pharma Co N.V's Share-based Compensation rose 87.72% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 81.45%. This contributed to the annual value of $33.6 million for FY2024, which is 36.82% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Share-based Compensation is $15.0 million, which was down 1.11% from $15.2 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Share-based Compensation peaked at $15.2 million during Q1 2025, and registered a low of $5.4 million during Q3 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $8.0 million (2024), whereas its average is $9.4 million.
  • Data for NewAmsterdam Pharma Co N.V's Share-based Compensation shows a peak YoY skyrocketed of 92.13% (in 2025) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Share-based Compensation (Quarterly) stood at $6.0 million in 2023, then surged by 56.76% to $9.4 million in 2024, then spiked by 87.72% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $15.2 million for Q2 2025, and $15.2 million during Q1 2025.